Mixed response to osimertinib and the beneficial effects of additional local therapy

BACKGROUND: Although non‐small cell lung cancers (NSCLCs) harboring EGFR mutations initially respond well to EGFR‐tyrosine kinase inhibitors (TKIs), they typically progress after approximately one year. The EGFR T790M mutation is the most common resistance mechanism. NSCLCs with T790M respond well t...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Thorac Cancer
Asıl Yazarlar: Shinno, Yuki, Goto, Yasushi, Sato, Jun, Morita, Ryo, Matsumoto, Yuji, Murakami, Shuji, Kanda, Shintaro, Horinouchi, Hidehito, Fujiwara, Yutaka, Yamamoto, Noboru, Ohe, Yuichiro
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons Australia, Ltd 2019
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6449255/
https://ncbi.nlm.nih.gov/pubmed/30735003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12991
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller